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We have examined the effect of zinc ions on low density lipoprotein (LDL) oxidation by macrophages, endothelial cells and iron ions in terms 
of the increased uptake of the LDL by macrophages. Zinc ions inhibited LDL modification by both cell types (which is dependent on the presence 
of iron ions in the culture medium) and by iron ions alone. As oxidised LDL is believed to be involved in atherogenesis, this raises the possibility 
that zinc may be an endogenous protective factor against atherosclerosis. 
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1. Introduction 
The role of low density lipoprotein (LDL) oxidation 
in the pathogenesis of atherosclerosis i  currently attract- 
ing a great deal of interest, with evidence for such a role 
accumulating from immunocytochemical nd biochemi- 
cal studies [l]. It has also been shown that antioxidants 
that prevent LDL oxidation in vitro also inhibit lesion 
development in hypercholesterolaemic animals [ 11, in- 
cluding primates [2]. All four cell types found in athero- 
sclerotic lesions (endothelial cells, smooth muscle cells, 
macrophages and lymphocytes) are capable of oxidising 
LDL in vitro [336]. 
be higher in myocardial infarction patients than in con- 
trol subjects [14]. There is therefore great uncertainty as 
to whether zinc is pro-atherogenic or anti-atherogenic. 
In the present study, we have tested the effect of zinc 
ions on LDL oxidation by macrophages, endothelial 
cells or ferrous ions in the presence of a reduced thiol 
(cysteine). Under the conditions used, zinc strongly in- 
hibited LDL oxidation by both cell types and by ferrous 
ionslcysteine. 
2. Materials and methods 
The trace element zinc has been shown to have anti- 
oxidant properties both in vitro and in vivo [7,8]. Kok 
et al. [9] have suggested that low serum levels of zinc may 
be associated with an increased risk of cardiovascular 
disease. It has been reported that zinc administration 
inhibits lesion development in cholesterol-fed rabbits, 
but the zinc decreased the serum cholesterol levels by 
78% in this study and hence no conclusion can be drawn 
about any possible effects that zinc may have had at the 
level of the arterial wall [lo]. Hooper et al. [l l] have 
reported that pharmacological levels of zinc decrease the 
plasma high density lipoprotein-cholesterol levels in hu- 
mans, whereas Shah et al. [12] have reported that zinc 
increases them. Klevay [13] has suggested that a high 
Zn/Cu ratio in the diet may be atherogenic, and the zinc 
level and zinc/copper ratio in hair have been shown to 
2.1. Materials 
Dulbecco’s modified Eagle’s medium (DMEM), foetal calf serum 
(FCS), gentamicin solution (10 mg/ml), penicillin/streptomycin solution 
(5,000 IU/5,000 pg per ml), amphotericin B solution (250 j&ml) and 
glutamine solution (200 mM) were purchased from Gibco, Uxbridge, 
Middlesex, UK. Ham’s F-10 medium and Nunc (25 cm’) culture flasks 
were from ICN Flow, High Wycombe, Bucks., UK. Ferrous sulphate 
and Phenol red solution (0.5% (w/v)) were from Sigma Chemical Co., 
Poole, Dorset, UK, zinc sulphate (Analar) was from BDH Chemicals, 
Poole, Dorset, UK and Costar twelve-well cluster plates (22 mm diam- 
eter wells) were purchased from Northumbria Biologicals Ltd., Cram- 
lington, Northumbria, UK. 
2.2. Isolation of LDL and radioiodination 
*Corresponding author. Fax: (44) (734) 310 180. 
LDL (d = 1.019-l .063 g/ml) was isolated from the blood of healthy 
volunteers by sequential density ultracentrifugation, as previously de- 
scribed [15], in the presence of EDTA. LDL (2 mg protein) was then 
labelled with “‘1 using an iodine monochloride method [lq. The radio- 
iodinated LDL was mixed with non-iodinated LDL to obtain a prep- 
aration of specific activity 20-40 cpm/ng protein, and diluted to 2 mg 
protein/ml with buffer containing 100 pM EDTA. This concentration 
of ‘251-labelled LDL was standardised so as to give 5 pM EDTA during 
LDL modification at 100 pg protein/ml, as EDTA can either inhibit or 
promote LDL oxidation depending on its concentration [17]. LDL 
preparations were no longer used 1 month after isolation. 
Abbreviations: DMEM, Dulbecco’s modified Eagle’s medium; EDTA, 2.3. Isolation and culture of mouse peritoneal macrophages 
ethylenediamine tetraacetic acid; FCS, foetal calf serum; LDL, low Resident peritoneal macrophages were isolated from female Swiss 
density lipoprotein. T.O. mice (Tuck & Son, Battlesbridge, Essex, UK) by peritoneal lavage 
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[18]. The cells were plated at 1.5 x lo6 peritoneal cells per well and 
incubated at 37°C under 5% CO, for 4 h to allow macrophage adher- 
ence, then washed with DMEM to remove lymphocytes before use in 
experiments. 
2.4. Isolation and culture of endothelial cells 
Bovine aortic endothelial cells were isolated and cultured as previ- 
ously described [19] in 25 cm’ culture flasks. The cells were subcultured 
into 22 mm wells and used to oxidise LDL. 
2.5. Modi$cation of LDL 
‘Z51-Labelled LDL (100 pug protein/ml) was incubated for the specified 
time (1622 h) at 37°C under 5% CO, with modifvine macroohaaes 
(macrophage-modified LDL), or with confluent we& 07 bovine’ ao&c 
endothelial cells (EC-modified LDL), or with 500 pM freshly dissolved 
cysteine or for the appropriate time in medium alone (control LDL). 
The incubation medium (0.75 ml/well) consisted of Ham’s F-10 medium 
supplemented with additional 3 PM FeSO,, Phenol red (12 &ml) and 
gentamicin (50 ,@ml). After incubation for the specified time, the 
medium was collected, centrifuged (13,000 rpm for 2.5 min in a MSE 
Microcentaur) to remove any detached cells, and then used for meas- 
urement of LDL uptake. 
2.6. Measurement of modified LDL uptake 
5774 mouse macrophage-like cells were plated at 1.5 x lo5 cells/well 
and used the following day to measure LDL uptake. Modified or 
control LDL was diluted to 1 Opg protein/ml in DMEM containing 20% 
(v/v) heat-inactivated FCS, penicillin/streptomycin (10 IU/lO pg per 
ml), amphotericin B (1 &ml) and glutamine (2 mM). The LDL was 
then incubated for 22-24 h with 5774 cells or cell-free wells (1 ml/well) 
and its rate of degradation was determined by the measurement of 
radioactive non-iodide trichloroacetic acid-soluble degradation prod- 
ucts [ 151. The 5774 cells were washed, lysed with 0.2 M NaOH and the 
cell protein and cell-associated radioactivity determined [16]. The low 
amounts of radioactivity remaining in the cell-free wells were sub- 
tracted from the cell-associated radioactivity. Values for degraded LDL 
and cell-associated LDL were combined to give total LDL uptake [20]. 
3. Results 
Ham’s F-10 medium, as obtained from ICN Flow, 
contains zinc sulphate (ZnS04.7Hz0) at 28.8 ,ug/l; hence 
all these studies have 0.1 ,uM as the base level of Zn2’. 
When the Zn2+ concentration was increased, a dose- 
dependent reduction in LDL modification by macro- 
phages, as measured by LDL uptake by other macro- 
phages, was observed, with a 50% reduction occurring 
at approximately 3 PM Zn2+ and a near total inhibition 
at 10 PM (Fig. 1). In other experiments, using a narrower 
range of zinc concentrations, the modification of LDL 
was reduced by 50% at 4-5 ,uM Zn2+. 
Similarly, when the Zn2+ concentration in incubations 
with bovine aortic endothelial cells was increased, a 
dose-dependent reduction in LDL modification was ob- 
served (Fig. 2). The concentration of Zn” required for 
50% reduction of LDL modification was between 1 and 
3 ,uM, and at 7.5 PM Zn2+ modification was totally inhib- 
ited. The modification of LDL by porcine aortic endo- 
thelial cells was similarly inhibited by zinc (data not 
shown). 
The addition of a thiol(500 PM freshly dissolved cys- 
teine) to Ham’s F-10 medium, supplemented with FeSO, 
to raise the iron concentration to 6 ,uM, produced a 
substantial modification of LDL, as found previously by 
2.5 
1 
Fig. 1. The effect of zinc ions on macrophage-mediated LDL oxidation. 
“‘1-Labelled LDL (100 pg protein/ml) was incubated for 16 h with 
macrophages (the adherent cells from 1.5 x lo6 peritoneal cells) (black 
bars) or cell-free wells (white bars) in Ham’s F-10 medium with or 
without additional zinc ions (baseline = 0.1 PM). The LDL was then 
diluted to 10 pg protein/ml in serum-containing medium and its rate of 
uptake by 5774 cells determined. Data are mean f S.E.M. (n = 3 wells 
of ‘modifying’ macrophages), and are representative of 3 experiments. 
Parthasarathy [21]. When the concentration of Zn2+ was 
increased above the base level of 0.1 ,uM, a dose-depend- 
ent reduction of LDL was observed, with a 50% reduc- 
tion between 3 and 10 ,uM (Fig. 3). 
4. Discussion 
Zinc is an essential trace element, required at about 15 
mg/day [7], which has been proposed to have antioxidant 
properties both in vitro and in vivo [7]. It has been sug- 
gested that low serum zinc levels may result in a predis- 
position to cardiovascular disease [9], but this is highly 
controversial. We report here that, under the conditions 
used, zinc ions effectively inhibit the oxidation of LDL 
by macrophages, endothelial cells or iron/cysteine. 
Iron ions have been shown to bind to LDL in 0.15 M 
NaCl in a form that is not removable by dialysis against 
0.15 M NaCl [22]. Iron ions can also peroxidase lipid 
micelles derived from LDL as efficiently as intact LDL 
[23], suggesting that iron binding to the lipid region of 
the LDL particle (presumably the ‘head groups’ of the 
phospholipids) is important. The antioxidant activity of 
zinc ions, which are not redox active, in other oxidation 
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systems has been postulated to be due to displacement 
of copper or iron ions from their binding sites [7,8]. This 
would explain the inhibition we have observed with zinc 
or LDL oxidation by cells (which is dependent on iron 
in the medium [24]) and by Fe”/cysteine, since the iron 
may be displaced from its binding sites on LDL. 
LDL oxidation by cells has an absolute requirement 
for cysteine [25]. Cysteine forms fairly strong complexes 
with iron, which may then react with molecular oxygen 
to form reactive oxygen species during the redox cycling 
of iron [26]. Zinc has been shown to inhibit the genera- 
tion of active oxygen species in this system [26], probably 
by displacement of iron from cysteine, since cysteine has 
a higher affmity for zinc than for iron [27]. Hence, in our 
system Zn2+ may displace iron from LDL or cysteine, 
resulting in the inhibition of LDL oxidation. 
Zinc is present in human atherosclerotic lesions [28] 
and is contained in plasma at a level of 15 PM, although 
almost all of it is bound to proteins (mainly a,-mac- 
roglobulin and albumin), with the free plasma zinc to- 
talling s 15 nM [29]. LDL oxidation is thought to occur 
locally in the arterial wall, however, where iron and cop- 
per may be released from their normal sequestered states 
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Fig. 2. The effect of zinc ions on LDL oxidation by bovine aortic 
endothelial cells. iZ51-Labelled LDL (100 pug protein/ml) was incubated 
for 22 h with confluent monolayers of cells (subculture number 10) (in 
22 mm diameter wells) (black bars) or cell-free wells (white bars) in 
Ham’s F-10 medium with or without additional zinc ions (base- 
line = 0.1 PM). The LDL was then diluted to 10 pug protein/ml in 
serum-containing medium and its rate of uptake by J774 cells deter- 
mined. Data are mean f S.E.M. (n = 3 wells of endothelial cells), and 
are representative of 7 experiments. 
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Fig. 3. The effect of zinc ions on iron/cysteine-mediated LDL oxidation. 
‘251-Labelled LDL (100 ,ug protein/ml) was incubated for 18 h in Ham’s 
F-10 medium supplemented with additional 3 pM FeSO, and 500 PM 
cysteine (black bars) or 3 PM FeSO, alone (white bars) with or without 
additional zinc ions (baseline = 0.1 PM). The LDL was then diluted to 
10 pg protein/ml in serum-containing medium and its rate of uptake by 
5774 cells determined. Data are mean + S.E.M. (n = 3 wells containing 
FeSO&ysteine). The results were confirmed in another experiment. 
and generate an oxidative stress [l]. In such an oxidative 
microenvironment, ‘free’ zinc may possibly be released 
from plasma proteins or cellular proteins from damaged 
cells. Metallothionein, for instance, is known to release 
its bound metals under conditions of oxidative stress 
1301. 
The inhibitory effect of zinc on LDL oxidation by 
iron-dependent processes at pH 7.4, both cell-free and 
cell-dependent, raises the possibility that zinc may act as 
an endogenous protective agent against atherogenesis. 
Much remains to be done, however, before we can ‘de- 
cide’ whether zinc is pro- or anti-atherogenic in humans, 
especially as we have very recently found that zinc can 
actually promote LDL oxidation by iromcysteine at 
acidic pH (unpublished data). 
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